Back to Newsroom

Symic Secures $25 Million in Series A-2 Financing to Advance Clinical-Stage Biotherapeutics Platform

SAN FRANCISCO, Dec. 1, 2015 /PRNewswire/ — Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced that it has secured $25 million in a Series A-2 financing to advance the company’s pipeline, including its lead candidates SB-030 and SB-061. The financing was led by Lilly Ventures and includes the participation by all existing major investors, as well as several new investors. This new funding brings the total capital raised by Symic to over $43 million since being founded in 2012.

Click here to read more